HER2 Testing Market Size, Share, and Growth Forecast, 2026 - 2033

The global HER2 testing market size is likely to be valued at US$179.2 million in 2026, and is expected to reach US$309.1 million by 2033, growing at a CAGR of 8.1% during the forecast period from 2026 to 2033, driven by rising incidence of HER2-positive breast and gastric cancers, increasing adoption of targeted therapies, and growing emphasis on personalized medicine. Increasing demand for accurate HER2 status determination to guide effective treatment decisions remains a major driver of HER2 testing market growth.

• Leading Region: North America, anticipated to account for a 42% market share in 2026, driven by advanced healthcare infrastructure, strong clinical guidelines, and high adoption of HER2 testing in precision oncology.
• Fastest-growing Region: Asia Pacific, fueled by rising cancer cases, expanding healthcare infrastructure, and a large patient pool requiring biomarker-based diagnostics.
• Dominant Cancer Type: Breast cancer is expected to dominate the HER2 testing market with ~75% share in 2026, driven by high incidence, mandatory HER2 testing guidelines, and strong demand for targeted therapies.
• Leading Technique: Fluorescence in situ hybridization (FISH) is projected to lead with ~40% share in 2026 due to its high accuracy, sensitivity, and role as a confirmatory test for precise HER2 status detection.

Driver - Increasing Awareness and Early Cancer Detection Programs

Growing public health initiatives and screening campaigns are significantly improving cancer detection rates and driving demand for diagnostic tests such as HER2 testing. Government-led programs in India, particularly under the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS), have expanded population-based screening and awareness activities at primary healthcare levels. These initiatives focus on educating individuals about early symptoms, promoting routine check-ups, and enabling timely diagnosis.

According to the Ministry of Health and Family Welfare, these figures highlight the scale of such efforts. As of 2025, more than 37 lakh women have been screened for breast cancer, along with over 19 lakhs for cervical cancer and more than 96 lakhs for oral cancer under national screening programs. This reflects a growing outreach of awareness-driven screening initiatives across the country. Government estimates indicate that India recorded over 14 lakh cancer cases in 2023, emphasizing the need for early detection strategies to reduce mortality. Despite historically low screening uptake, less than 2% of eligible women are undergoing screening as per NFHS-5 data. Ongoing awareness campaigns and community-level interventions are steadily improving participation.

Rising Prevalence of Breast and Gastric Cancers

The growing burden of cancer, particularly among women, is significantly contributing to the demand for advanced diagnostic solutions such as HER2 testing. Breast cancer has emerged as one of the most diagnosed cancers in India, with government data indicating a steady rise in incidence over recent years. According to data presented in Parliament, breast cancer cases increased from approximately 2.13 lakh in 2021 to nearly 2.4 lakh in 2025, reflecting a substantial rise in disease burden. This upward trend highlights the expanding patient pool requiring biomarker-based diagnostic evaluation.

The overall cancer burden in India is also increasing at a notable pace. Government estimates show that total cancer cases rose from about 14.26 lakh in 2021 to nearly 15.7 lakh in 2025, with an average annual increase of around 28,000 cases. This consistent growth underscores the escalating need for early and precise diagnostic tools across oncology. Gastric cancer, although relatively lower in incidence compared to breast cancer, remains a significant contributor to cancer-related mortality and is among the common cancers in the country. It is also associated with poor prognosis due to late-stage diagnosis in many cases. The increasing incidence of these cancers, combined with late detection challenges, is driving the need for accurate biomarker identification.

Restraint - High Cost of Advanced Testing Techniques

The cost burden associated with advanced diagnostic technologies remains a significant barrier to the widespread adoption of HER2 testing. Techniques such as immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS) require expensive instruments, specialized reagents, and controlled laboratory environments. In addition to capital investment, recurring costs related to maintenance, quality control, and consumables further increase overall expenditure for healthcare providers.

Operational costs are also elevated due to the need for skilled pathologists and trained laboratory personnel to ensure accurate test interpretation. This makes it difficult for smaller diagnostic centers and hospitals, particularly in low- and middle-income regions, to implement such technologies. Testing services are often concentrated in urban or well-equipped facilities, limiting access for a broader population.

Lack of Standardization in Testing Protocols

Variability in diagnostic procedures and interpretation criteria remains a key challenge in HER2 testing. Different laboratories may follow slightly different protocols for sample preparation, staining techniques, and scoring systems, particularly in methods like immunohistochemistry (IHC) and in situ hybridization (ISH). These inconsistencies can lead to differences in test results, even when evaluating the same patient sample.

Subjective interpretation by pathologists further contributes to variability, especially in borderline or equivocal cases where HER2 expression is not clearly positive or negative. Inconsistent reporting standards and differences in quality control practices across laboratories can also affect the reliability of results. Such variability may lead to misclassification of HER2 status, potentially impacting treatment decisions and patient outcomes.

Opportunity - Advancements in Next-Generation Sequencing (NGS) and Molecular Diagnostics

Continuous innovation in genomic technologies is significantly transforming cancer diagnostics by enabling more precise and comprehensive tumor profiling. Unlike traditional single-gene tests, next-generation sequencing (NGS) allows simultaneous analysis of hundreds of genes from a single sample, improving efficiency and reducing the need for multiple tests. This capability is particularly valuable in HER2 testing, where identifying gene amplifications and mutations is critical for selecting targeted therapies.

NGS-based molecular diagnostics are also enhancing clinical decision-making by uncovering actionable mutations that may not be detected through conventional methods. Studies have shown that NGS can identify clinically relevant genetic alterations in a large proportion of cancer patients, supporting more personalized treatment strategies and improving outcomes. The approval of an NGS-based companion diagnostic by the U.S. Food and Drug Administration (FDA) to detect HER2 (ERBB2) mutations in cancer patients. This test helps identify individuals eligible for targeted therapies such as antibody-drug conjugates, demonstrating the growing integration of NGS into routine oncology practice.

Growing Focus on HER2-Low and New Cancer Indications

Expanding research focus beyond traditional HER2-positive cancers is creating new growth avenues for HER2 testing, particularly with the identification of HER2-low expression as a clinically relevant category. Historically, patients classified as HER2-negative had limited access to targeted therapies. However, emerging evidence shows that a substantial proportion of these patients express low levels of HER2, making them eligible for newer treatment approaches.

The U.S. Food and Drug Administration approved a targeted therapy for HER2-low breast cancer, defining this category as tumors with IHC 1+ or IHC 2+/ISH-negative expression. This approval was supported by a clinical trial involving 557 patients, demonstrating the expanding therapeutic scope for this subgroup. Further advancement came in 2025 with expanded approval to include HER2-ultralow patients along with companion diagnostic assays, reinforcing the importance of precise HER2 classification. From a prevalence perspective, studies indicate that around 60% of HER2-negative breast cancers fall into the HER2-low category, significantly enlarging the target patient population for testing and treatment.

Cancer Type Insights

Breast cancer is anticipated to dominate, accounting for 75% of the revenue share in 2026, fueled by its high global incidence and the routine use of HER2 status assessment in clinical practice. Standardized testing guidelines recommend HER2 evaluation for all newly diagnosed invasive breast cancer cases, ensuring consistent demand for diagnostic testing. The availability of multiple HER2-targeted therapies further reinforces the need for accurate and timely testing. Roche has developed diagnostic solutions such as the VENTANA HER2 Dual ISH DNA Probe Cocktail and the PATHWAY HER2 (4B5) assay, which are extensively utilized as companion diagnostics for breast cancer. These tests have received approval from the U.S. Food and Drug Administration and are used to accurately determine HER2 status in patients.

Gastric cancer represents the fastest-growing segment, due to increasing recognition of HER2 overexpression in a subset of patients. Growing clinical evidence has highlighted the importance of HER2 status in guiding treatment decisions, particularly for advanced and metastatic cases. The expansion of targeted therapies, including monoclonal antibodies and antibody-drug conjugates, has significantly increased the need for accurate HER2 testing in gastric cancer. A collaboration between Daiichi Sankyo and AstraZeneca has led to the development. Their therapy, trastuzumab deruxtecan (Enhertu), has been approved by the U.S. Food and Drug Administration for the treatment of patients with HER2-positive gastric or gastroesophageal junction cancer. The approval was supported by clinical trial data involving 188 patients, where the drug achieved a response rate of 40.5%, significantly higher than 11.3% observed with standard chemotherapy, along with demonstrating improved overall survival outcomes.

Technique Insights

Fluorescence in situ hybridization is projected to dominate, holding 40% share in 2026, propelled by its high accuracy in detecting HER2 gene amplification at the molecular level. It is often used as a confirmatory test, especially in cases with equivocal immunohistochemistry (IHC) results, ensuring precise classification of HER2 status. The technique offers superior sensitivity and specificity, reducing the risk of false results and supporting effective treatment decisions. Roche offers the VENTANA HER2 Dual ISH DNA Probe Cocktail, a FISH/ISH-based diagnostic assay that has received approval from the U.S. Food and Drug Administration. This companion diagnostic is designed to detect HER2 gene amplification in breast cancer patients, enabling the precise determination of HER2 status and helping clinicians identify individuals who are suitable candidates for targeted treatments such as trastuzumab.

Chromogenic in situ hybridization (CISH) represents the fastest-growing technique, with its practical and cost-effective advantages. Unlike fluorescence-based methods, CISH can be analyzed using standard bright-field microscopes, making it more accessible for routine pathology laboratories. This eliminates the need for specialized fluorescence equipment and allows easier interpretation alongside tissue morphology. CISH also offers relatively lower operational costs while maintaining good accuracy in detecting HER2 gene amplification. Chromogenic in situ hybridization (CISH) for HER2 testing was developed by Zymed Laboratories, which is now part of Thermo Fisher Scientific. The company introduced the SPoT-Light HER2 CISH Kit, a diagnostic assay developed to identify HER2 gene amplification through chromogenic signals that can be observed using standard bright-field microscopy. Clinical evaluations have demonstrated that this method delivers reliable results while enabling seamless integration into routine pathology practices, eliminating the need for specialized fluorescence-based equipment.

North America HER2 Testing Market Trends

North America is projected to dominate, accounting for 42% of revenue in 2026, powered by its advanced healthcare infrastructure, high awareness of cancer diagnostics, and strong emphasis on precision medicine. The region benefits from well-established clinical guidelines that recommend routine HER2 testing for breast and certain gastric cancer patients, ensuring consistent demand across hospitals and diagnostic laboratories.

The widespread adoption of companion diagnostics alongside targeted therapies has made HER2 testing a standard step in oncology treatment planning. In addition, the region is witnessing rapid integration of advanced technologies such as next-generation sequencing (NGS), digital pathology, and automated testing platforms, improving diagnostic accuracy and turnaround time. According to the American Cancer Society, the U.S. is expected to record around 310,720 new breast cancer cases in 2024, reflecting a large patient population requiring HER2 testing.

Europe HER2 Testing Market Trends

Europe is supported by strong healthcare systems and widespread adoption of standardized cancer diagnostic practices. Countries across the region follow well-established clinical guidelines, such as those from the European Society for Medical Oncology, which recommend routine HER2 testing for breast and certain gastric cancers. This ensures consistent demand for testing across hospitals and pathology laboratories.

The region is increasingly focused on precision oncology, where HER2 status plays a critical role in guiding targeted therapy decisions. The adoption of advanced diagnostic technologies, including automated immunohistochemistry (IHC), in situ hybridization (ISH), and next-generation sequencing (NGS), is improving accuracy and efficiency in clinical settings. Rising cancer incidence is also contributing to market growth. According to the European Commission, Europe accounts for a significant share of global cancer cases, with over 2.7 million new cancer cases reported annually, highlighting a large patient base requiring biomarker testing.

Asia Pacific HER2 Testing Market Trends

Asia Pacific is likely to be the fastest-growing region, propelled by expanding healthcare infrastructure and a rapidly increasing cancer burden. Countries such as China, India, Japan, and South Korea are witnessing a rise in breast and gastric cancer cases, creating a strong demand for accurate diagnostic testing. According to the World Health Organization, a significant proportion of global cancer cases occur in Asia, highlighting the region’s large patient pool requiring biomarker-based diagnostics.

The growing emphasis on early detection and screening programs is supported by government initiatives aimed at improving cancer diagnosis at earlier stages. The region is experiencing increased adoption of advanced diagnostic technologies, including immunohistochemistry (IHC), in situ hybridization (ISH), and next-generation sequencing (NGS), particularly in urban and private healthcare settings. Cost-effective techniques such as chromogenic in situ hybridization (CISH) are also gaining traction in resource-limited areas.

The global HER2 testing market is highly competitive, with major diagnostic companies striving to enhance test accuracy, turnaround time, and clinical relevance in treatment decision-making. Key players such as Abbott, F. Hoffmann-La Roche Ltd., Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Leica Biosystems (Danaher Corporation), and Empire Genomics, Inc. (Biocare Medical, LLC) are actively competing through innovation and strategic expansion.

Companies are focusing on advanced technologies such as fluorescence in situ hybridization (FISH) and chromogenic in situ hybridization (CISH) to improve diagnostic precision. Strong regulatory compliance and collaborations with oncology centers further strengthen their market position. Additionally, partnerships with pharmaceutical firms for companion diagnostics are becoming increasingly important, aligning testing solutions with targeted therapies.

Key Industry Developments:

• In March 2026, Guardant Health, Inc. announced that real-world evidence generated from its InfinityAI platform contributed to the approval of ENHERTU® (trastuzumab deruxtecan). The therapy, developed and commercialized by Daiichi Sankyo, received approval in Japan for the treatment of patients with HER2-positive (HER2 [ERBB2] gene amplification or immunohistochemistry [IHC] 3+) advanced or recurrent solid tumors that were refractory or intolerant to standard therapies.
• In December 2025, Roche announced that the U.S. Food and Drug Administration approved additional indications for its PATHWAY® anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody and VENTANA® HER2 Dual ISH DNA Probe Cocktail tests. The company stated that these approvals enabled the tests to identify patients with HER2-positive metastatic breast cancer (mBC) who were eligible for treatment with ENHERTU® (trastuzumab deruxtecan) in combination with pertuzumab.